Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Inclusion Criteria:

1. Adult women >/=18 years old

2. Confirmed diagnosis of high-grade serous epithelial ovarian, primary peritoneal, orfallopian tube cancer

3. Confirmed high FRα expression by regulatory-agency approved Ventana FOLR1 (FOLR1-2.1)

4. Relapsed disease after frontline (first-line) platinum-based chemotherapy and mustbe plantinum-sensitive

5. Willing and able to sign the informed consent form (ICF) and adhere to protocolrequirements

6. Negative pregnancy test and willing to use highly effective contraceptive method(s)while on study medication and for at least 7 months after the last dose of MIRV and 6 months after the last dose of bevacizumab

Exclusion Criteria:

1. Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed tumorscontaining any of the above or low grade/borderline ovarian tumor

2. More than one line of prior chemotherapy before current/planned triplet therapy

3. PD (progressive disease) while on or following platinum-based therapy

4. Prior or whole-pelvis or wide-field radiotherapy

5. > Grade 1 peripheral neuropathy

6. History of or concurrent ocular disorders

7. Grade 4 thromboembolic events

8. Not appropriate for bevacizumab treatment

9. Requiring use of folate-containing supplements

10. Prior hypersensitivity to monoclonal antibodies

11. Pregnant or breatfeeding women

12. Received prior MIRV or other FRα-targeting agents

13. Untreated or symptomatic central nervous system metastases

14. History of other malignancy within 3 years prior to signing study consent